Oculis Holding AG
NASDAQ:OCSBiotechnology
-$0.28 today
- Market cap
- $456.20M
- Beta
- 0.13
- P/E (TTM)
- -5.5
- EPS (TTM)
- -$1.61
Volume 0.31M
Average 0.65M
OCS Cost of Revenue
Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.
Oculis Holding AGNASDAQ: OCS
Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026
Cost of revenue remains negative
Q1 FY2026 cost of revenue was CHF 157.43K, compared with CHF 0 a year earlier. Trailing-twelve-month cost of revenue was CHF 15.07M.
Context
- Cost of revenue increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly cost of revenue holds near CHF 157.43K or moves back toward the trailing-twelve-month quarterly average of CHF 3.77M.
Sources:Income StatementText generated from reported figures; not investment advice.
Cost of Revenue history
CHF · from the income statement
- Latest · FY2025
- 0 CHF
- Year-over-year change
- -100.0%
| Period | Period end | Cost of Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | -100.0% |
| FY2024 | 2024-12-31 | 52.08M | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Cost of Revenue vs competitors
How OCS compares with its peers on the latest reported figures
- Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
- Cost of revenue amounts to 2989.4% of revenue for OCS, versus a peer median of 24.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $69.57M USD | +28.3% | +38.8% | 25.9% | |
| LTM Mar 2026 | CHF 15.07M CHF | — | — | 2989.4% | |
| LTM Mar 2026 | $6.64M USD | +19.4% | +13.1% | 12.8% | |
| LTM Mar 2026 | $1.79M USD | -52.4% | -37.2% | 23.5% | |
| LTM Mar 2026 | $1.54M USD | +977.1% | +54.6% | 460.9% | |
| FY2025 | $2.56K USD | -33.7% | +1.9% | — | |
| Peer median (excluding OCS) | — | +19.4% | +13.1% | 24.7% | |
Competitors are the stored peer set for OCS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 686K | 0 |
| Cost of Revenue | 0 | 0 | 0 | 52.08M | 0 |
| Gross Profit | 0 | 0 | 0 | (51.4M) | 0 |
| Gross Margin | — | — | — | -7492.3% | — |
| Research & Development | 9.57M | 22.22M | 29.25M | 52.08M | 54.52M |
| Selling, General & Admin | 4.1M | 6.74M | 14.72M | 21.81M | 24.63M |
| Operating Expenses | 13.23M | 32.38M | 80.71M | 21.81M | 79.15M |
| Depreciation & Amortization | 235K | 299K | 287K | 406K | 521.45K |
| EBITDA | (13.17M) | (31.9M) | (87.09M) | (85.53M) | (93.37M) |
| EBITDA Margin | — | — | — | -12468.1% | — |
| Operating Income | (13.23M) | (32.38M) | (80.71M) | (73.2M) | (79.15M) |
| Operating Margin | — | — | — | -10671.1% | — |
| Interest Income | 21K | 126K | 1.59M | 2.17M | 1.69M |
| Interest Expense | 5.12M | 6.44M | 1.46M | 639K | 795.55K |
| Other Income / Expenses | (5.29M) | (6.27M) | (7.98M) | (12.73M) | (15.54M) |
| Income Before Tax | (18.52M) | (38.64M) | (88.7M) | (85.94M) | (94.69M) |
| Pre-Tax Margin | — | — | — | -12527.3% | — |
| Income Tax Expense | 27K | 55K | 107K | (160K) | 177.64K |
| Net Income | (18.55M) | (38.7M) | (88.8M) | (85.78M) | (94.51M) |
| Net Margin | — | — | — | -12503.9% | — |
| EPS (Basic) | (0.57) | (1.18) | (2.97) | (2.12) | (1.81) |
| EPS (Diluted) | (0.57) | (1.18) | (2.97) | (2.12) | (1.81) |
| Weighted Avg Shares | 32.73M | 32.73M | 29.9M | 40.41M | 52.36M |
| Weighted Avg Shares (Diluted) | 32.73M | 32.73M | 29.9M | 40.41M | 52.36M |
Oculis Holding AG
NASDAQ:OCS
Intrinsic Alpha fair value
Locked
Current Price
$7.39
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.